Cargando…

Microbial antigens-loaded myeloma cells enhance Th2 cell proliferation and myeloma clonogenicity via Th2–myeloma cell interaction

BACKGROUND: Myeloma cells retain B cell functions, considered to be potential antigen presenting cells, yet there is little information regarding promoting Th2 cell proliferation or the direct effects to myeloma on the Th2 cells stimulated by microbial antigens-loaded myeloma cells. METHODS: Mixed l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tian, Faqing, Lu, Bo, Chen, Ziren, Liu, Junru, Ji, Delan, Li, Juheng, Tang, Meiqin, Zhu, Wei, Li, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6929311/ https://www.ncbi.nlm.nih.gov/pubmed/31870332 http://dx.doi.org/10.1186/s12885-019-6469-4

Ejemplares similares

The antibiotic chloramphenicol may be an effective new agent for inhibiting the growth of multiple myeloma
por: Tian, Faqing, et al.
Publicado: (2016)

Enhancement of myeloma development mediated though myeloma cell-Th2 cell interactions after microbial antigen presentation by myeloma cells and DCs
por: Tian, F, et al.
Publicado: (2012)

MicroRNA-497 inhibits multiple myeloma growth and increases susceptibility to bortezomib by targeting Bcl-2
por: Tian, Faqing, et al.
Publicado: (2019)

Enhancement of clonogenicity of human multiple myeloma by dendritic cells
por: Kukreja, Anjli, et al.
Publicado: (2006)

Natural killer cells efficiently target multiple myeloma clonogenic tumor cells
por: Leivas, Alejandra, et al.
Publicado: (2021)

Evidence that multiple myeloma may be regulated by homeostatic control mechanisms: correlation of changes in the number of clonogenic myeloma cells in vitro with clinical response.
por: Maitland, J. A., et al.
Publicado: (1990)

Clonogenic Multiple Myeloma Cells have Shared stemness Signature Associated with Patient Survival
por: Reghunathan, Renji, et al.
Publicado: (2013)

The Role of Regulatory T Cells and TH17 Cells in Multiple Myeloma
por: Braga, Walter M. T., et al.
Publicado: (2012)

Gut microbiota deficiency ameliorates multiple myeloma and myeloma-related bone disease by Th17 cells in mice models
por: Liu, Jia, et al.
Publicado: (2023)

Loss of p53 enhances the tumor-initiating potential and drug resistance of clonogenic multiple myeloma cells
por: Chang, Yu-Tai, et al.
Publicado: (2023)

Telomerase Inhibition Targets Clonogenic Multiple Myeloma Cells through Telomere Length-Dependent and Independent Mechanisms
por: Brennan, Sarah K., et al.
Publicado: (2010)

Bortezomib Reduces the Tumorigenicity of Multiple Myeloma via Downregulation of Upregulated Targets in Clonogenic Side Population Cells
por: Nara, Miho, et al.
Publicado: (2013)

Detection of myeloma cell-derived microvesicles: a tool to monitor multiple myeloma load
por: Liu, Zhao-Yun, et al.
Publicado: (2023)

Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients
por: Bera, T K, et al.
Publicado: (2018)

Mitochondrial-Targeted Decyl-Triphenylphosphonium Enhances 2-Deoxy-D-Glucose Mediated Oxidative Stress and Clonogenic Killing of Multiple Myeloma Cells
por: Schibler, Jeanine, et al.
Publicado: (2016)

Chimeric antigen receptor T cell therapy for multiple myeloma
por: Hasegawa, Kana, et al.
Publicado: (2019)

Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma
por: Hosen, Naoki
Publicado: (2019)

Chimeric antigen receptor T cell therapies for multiple myeloma
por: Wu, Chao, et al.
Publicado: (2019)

Chimeric antigen receptor T-cell therapy for multiple myeloma
por: Wang, Zehua, et al.
Publicado: (2022)

Oscillating expression of interleukin-16 in multiple myeloma is associated with proliferation, clonogenic growth, and PI3K/NFKB/MAPK activation
por: Templin, Julia, et al.
Publicado: (2017)

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network
por: Moreau, Philippe, et al.
Publicado: (2019)

Heparanase promotes myeloma progression by inducing mesenchymal features and motility of myeloma cells
por: Li, Juan, et al.
Publicado: (2016)

European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma
por: Bruno, Benedetto, et al.
Publicado: (2021)

Targeting Proliferating Cell Nuclear Antigen and Its Protein Interactions Induces Apoptosis in Multiple Myeloma Cells
por: Müller, Rebekka, et al.
Publicado: (2013)

RUNX2 promotes the suppression of osteoblast function and enhancement of osteoclast activity by multiple myeloma cells
por: Huang, Beihui, et al.
Publicado: (2023)

Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival
por: Di Lullo, Giulia, et al.
Publicado: (2015)

Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA
por: Oberle, Anna, et al.
Publicado: (2017)

Targeting SIRT1 to inhibit the proliferation of multiple myeloma cells
por: Lu, Bo, et al.
Publicado: (2021)

Effects of Voltage-Gated K(+) Channel on Cell Proliferation in Multiple Myeloma
por: Wang, Wei, et al.
Publicado: (2014)

Elevated Th22 as well as Th17 cells associated with therapeutic outcome and clinical stage are potential targets in patients with multiple myeloma
por: Wang, Min, et al.
Publicado: (2015)

Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells
por: Stefka, A T, et al.
Publicado: (2016)

Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease
por: Garcia-Gomez, Antonio, et al.
Publicado: (2014)

Anti-SOX2 T cells may prevent myeloma
por: Bashyam, Hema
Publicado: (2007)

Expression and Importance of TMED2 in Multiple Myeloma Cells
por: Ge, Xueling, et al.
Publicado: (2020)

Clinical significance of granule‐containing myeloma cells in patients with newly diagnosed multiple myeloma
por: Suzuki, Kazuhito, et al.
Publicado: (2016)

Adoptive cell therapy using PD-1(+) myeloma-reactive T cells eliminates established myeloma in mice
por: Jing, Weiqing, et al.
Publicado: (2017)

A tumor-associated antigen specific for human kappa myeloma cells
Publicado: (1983)

A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma
por: Atrash, Shebli, et al.
Publicado: (2021)

Chimeric Antigen Receptor T Cell Therapy and Its Significance in Multiple Myeloma
por: Padda, Jaskamal, et al.
Publicado: (2021)

Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma
por: Fang, Yi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fo23r6r1n2t70ftpfvokt4aln1